Stock MCK MCKESSON CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Financials McKesson Corporation

Equities

MCK

US58155Q1031

Pharmaceuticals

Market Closed - Nyse
Other stock markets
 04:00:02 2024-05-24 pm EDT 		5-day change 1st Jan Change
560.7 USD +0.48% Intraday chart for McKesson Corporation -0.67% +21.11%
May. 17 JPMorgan Adjusts McKesson Price Target to $656 From $589 MT
May. 16 McKesson Seeks Acquisitions CI

Valuation

Fiscal Period: Marzo 2020 2021 2022 2023 2024 2025 2026 2027
Capitalization 1 23,952 31,044 45,858 48,757 70,547 72,887 - -
Enterprise Value (EV) 1 27,324 31,914 48,205 49,673 71,593 72,567 70,227 66,430
P/E ratio 27.3 x -6.9 x 42.3 x 14.2 x 24 x 19.2 x 17.9 x 15.4 x
Yield 1.2% 0.86% 0.6% 0.59% 0.45% 0.48% 0.52% 0.46%
Capitalization / Revenue 0.1 x 0.13 x 0.17 x 0.18 x 0.23 x 0.2 x 0.19 x 0.17 x
EV / Revenue 0.12 x 0.13 x 0.18 x 0.18 x 0.23 x 0.2 x 0.18 x 0.16 x
EV / EBITDA 6.34 x 7.33 x 9.14 x 9.27 x 13.5 x 12.3 x 11 x 9.53 x
EV / FCF 7.06 x 8.18 x 12.4 x 10.8 x 19.7 x 14.9 x 14.4 x 12 x
FCF Yield 14.2% 12.2% 8.09% 9.26% 5.07% 6.7% 6.95% 8.32%
Price to Book 4.3 x 179 x -19.5 x -27.3 x -36.5 x -105 x 34.4 x 14.5 x
Nbr of stocks (in thousands) 177,081 159,167 149,798 136,939 131,408 129,986 - -
Reference price 2 135.3 195.0 306.1 356.0 536.8 560.7 560.7 560.7
Announcement Date 5/20/20 5/6/21 5/5/22 5/8/23 5/7/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: Marzo 2020 2021 2022 2023 2024 2025 2026 2027
Net sales 1 231,051 238,228 263,966 276,711 308,951 358,134 385,968 416,624
EBITDA 1 4,309 4,354 5,276 5,357 5,287 5,889 6,383 6,968
EBIT 1 3,849 3,890 4,849 4,985 4,901 5,415 5,790 6,382
Operating Margin 1.67% 1.63% 1.84% 1.8% 1.59% 1.51% 1.5% 1.53%
Earnings before Tax (EBT) 1 1,144 -5,034 1,928 4,630 3,789 4,696 4,780 5,619
Net income 1 900 -4,539 1,114 3,560 3,002 3,717 3,900 4,317
Net margin 0.39% -1.91% 0.42% 1.29% 0.97% 1.04% 1.01% 1.04%
EPS 2 4.950 -28.26 7.230 25.03 22.39 29.21 31.39 36.38
Free Cash Flow 1 3,868 3,901 3,899 4,601 3,627 4,865 4,884 5,526
FCF margin 1.67% 1.64% 1.48% 1.66% 1.17% 1.36% 1.27% 1.33%
FCF Conversion (EBITDA) 89.77% 89.6% 73.9% 85.89% 68.6% 82.61% 76.51% 79.31%
FCF Conversion (Net income) 429.78% - 350% 129.24% 120.82% 130.87% 125.23% 128.02%
Dividend per Share 2 1.620 1.670 1.830 2.090 2.400 2.697 2.932 2.582
Announcement Date 5/20/20 5/6/21 5/5/22 5/8/23 5/7/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: March 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2 2025 Q3 2025 Q4 2026 Q1
Net sales 1 68,614 66,102 67,154 70,157 70,490 68,910 74,483 77,215 80,898 76,355 82,861 91,601 95,948 91,440 92,673
EBITDA 1 1,377 1,296 1,229 1,291 1,484 1,353 1,267 1,303 1,358 1,359 1,360 1,441 1,527 1,568 1,512
EBIT 1 1,273 1,204 1,137 1,197 1,393 1,258 1,170 1,208 1,261 1,262 1,263 1,331 1,406 1,464 1,386
Operating Margin 1.86% 1.82% 1.69% 1.71% 1.98% 1.83% 1.57% 1.56% 1.56% 1.65% 1.52% 1.45% 1.47% 1.6% 1.5%
Earnings before Tax (EBT) - - - - 1,448 932 1,091 916 612 1,170 - - - - -
Net income 1 -7 368 768 926 1,079 787 958 664 589 791 845.2 915.7 986 1,002 947
Net margin -0.01% 0.56% 1.14% 1.32% 1.53% 1.14% 1.29% 0.86% 0.73% 1.04% 1.02% 1% 1.03% 1.1% 1.02%
EPS 2 -0.0400 2.470 5.260 6.420 7.660 5.710 7.020 4.920 4.420 6.020 6.585 7.158 7.790 7.932 7.520
Dividend per Share 2 0.4700 0.4700 0.4700 0.5400 0.5400 0.5400 0.5400 0.6200 0.6200 0.6200 0.6271 0.6874 0.6946 0.7018 0.7172
Announcement Date 2/2/22 5/5/22 8/3/22 11/1/22 2/1/23 5/8/23 8/2/23 11/1/23 2/7/24 5/7/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: March 2020 2021 2022 2023 2024 2025 2026 2027
Net Debt 1 3,372 870 2,347 916 1,046 - - -
Net Cash position 1 - - - - - 320 2,660 6,457
Leverage (Debt/EBITDA) 0.7825 x 0.1998 x 0.4448 x 0.171 x 0.1978 x - - -
Free Cash Flow 1 3,868 3,901 3,899 4,601 3,627 4,865 4,884 5,526
ROE (net income / shareholders' equity) 41.2% 105% - - - - 379% 217%
ROA (Net income/ Total Assets) 4.49% 4.42% 5.69% 5.87% 5.67% 5.83% 5.98% 6.13%
Assets 1 20,036 -102,780 19,570 60,612 52,943 63,741 65,210 70,457
Book Value Per Share 2 31.40 1.090 -15.70 -13.10 -14.70 -5.360 16.30 38.70
Cash Flow per Share 2 24.00 28.30 28.80 36.30 32.20 47.20 43.30 56.60
Capex 1 506 641 535 558 687 702 717 745
Capex / Sales 0.22% 0.27% 0.2% 0.2% 0.22% 0.2% 0.19% 0.18%
Announcement Date 5/20/20 5/6/21 5/5/22 5/8/23 5/7/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for McKesson Corporation

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
560.7 USD
Average target price
584.1 USD
Spread / Average Target
+4.16%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Pharmaceuticals Wholesale

1st Jan change Capi.
MCKESSON CORPORATION Stock McKesson Corporation
+21.11% 72.89B
CARDINAL HEALTH, INC. Stock Cardinal Health, Inc.
-4.38% 23.48B
SINOPHARM GROUP CO. LTD. Stock Sinopharm Group Co. Ltd.
+4.16% 8.51B
SHANGHAI PHARMACEUTICALS HOLDING CO., LTD Stock Shanghai Pharmaceuticals Holding Co., Ltd
+9.26% 8.42B
HUADONG MEDICINE CO., LTD Stock Huadong Medicine Co., Ltd
-24.53% 7.56B
H. LUNDBECK A/S Stock H. Lundbeck A/S
+13.31% 5.22B
EBOS GROUP LIMITED Stock EBOS Group Limited
0.00% 4.2B
GALENICA AG Stock Galenica AG
-1.31% 3.91B
JOINTOWN PHARMACEUTICAL GROUP CO., LTD Stock Jointown Pharmaceutical Group Co., Ltd
+6.13% 3.91B
CHINA NATIONAL MEDICINES CORPORATION LTD. Stock China National Medicines Corporation Ltd.
+21.14% 3.61B
Pharmaceuticals Wholesale
  1. Stock Market
  2. Equities
  3. MCK Stock
  4. Financials McKesson Corporation